Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

2.3K
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
2.3K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

959
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
959
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.6K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

1.1K
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

1.2K
Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
Antiepileptic Drugs: Calcium Channel Blockers01:17

Antiepileptic Drugs: Calcium Channel Blockers

1.6K
Calcium channel blockers, a class of antiepileptic drugs, regulate the flow of calcium ions within neurons.
Calcium channel blockers exert their antiepileptic effects by targeting T-type calcium channels, which are integral to transmitting nerve signals in the central nervous system. These channels allow the passage of calcium ions, which are vital for neuronal communication. By inhibiting T-type calcium channels, calcium channel blockers effectively reduce the release of neurotransmitters and...
1.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A clinical evaluation of amlexanox oral adhesive pellicles in the treatment of recurrent aphthous stomatitis and comparison with amlexanox oral tablets: a randomized, placebo controlled, blinded, multicenter clinical trial.

Trials·2009
Same author

Long-term assessment of bladder and bowel dysfunction after radical hysterectomy.

Gynecologic oncology·2009
Same author

Oxidative stress contributes to silica nanoparticle-induced cytotoxicity in human embryonic kidney cells.

Toxicology in vitro : an international journal published in association with BIBRA·2009
Same author

A rapid and simple method for identifying Mycobacterium tuberculosis W-Beijing strains based on detection of a unique mutation in Rv0927c by PCR-SSCP.

Microbes and infection·2009
Same author

CO oxidation over AuPd(100) from ultrahigh vacuum to near-atmospheric pressures: the critical role of contiguous Pd atoms.

Journal of the American Chemical Society·2009
Same author

Daunorubicin-loaded magnetic nanoparticles of Fe(3)O(4) greatly enhance the responses of multidrug-resistant K562 leukemic cells in a nude mouse xenograft model to chemotherapy.

Zhongguo shi yan xue ye xue za zhi·2009

Related Experiment Video

Updated: Mar 31, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.4K

Acetazolamide Attenuates Thrombin-Induced Hydrocephalus.

Feng Gao1,2, Mingzhe Zheng2,3, Ya Hua1

  • 1Department of Neurology, The 2nd Affiliate Hospital, Zhejiang University, Zhejiang, China.

Acta Neurochirurgica. Supplement
|October 15, 2015
PubMed
Summary

Thrombin injection in rats caused significant hydrocephalus and brain injury. Acetazolamide treatment reduced this thrombin-induced hydrocephalus by decreasing cerebrospinal fluid production.

Keywords:
AcetazolamideCerebral ventriclesHydrocephalusThrombin

More Related Videos

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.7K
Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier
08:40

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier

Published on: November 12, 2013

17.2K

Related Experiment Videos

Last Updated: Mar 31, 2026

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema
08:44

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

9.4K
A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia
06:01

A Thrombotic Stroke Model Based On Transient Cerebral Hypoxia-ischemia

Published on: August 18, 2015

15.7K
Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier
08:40

Improved Method for the Preparation of a Human Cell-based, Contact Model of the Blood-Brain Barrier

Published on: November 12, 2013

17.2K

Area of Science:

  • Neuroscience
  • Pharmacology

Background:

  • Thrombin is implicated in brain injury following hemorrhage.
  • Hydrocephalus is a potential complication of intraventricular hemorrhage.

Purpose of the Study:

  • To investigate the effect of acetazolamide on thrombin-induced hydrocephalus in a rat model.
  • To determine if acetazolamide can mitigate brain injury associated with thrombin-induced hydrocephalus.

Main Methods:

  • Rats received intraventricular injections of saline or thrombin.
  • Thrombin-injected rats were subsequently treated with vehicle or acetazolamide (30 mg/kg, IP).
  • Lateral ventricle volumes were measured using MRI, and brain histology was performed at 24 hours.

Main Results:

  • Intraventricular thrombin significantly increased lateral ventricle volume and caused ventricular wall damage compared to saline.
  • Acetazolamide treatment markedly attenuated the thrombin-induced increase in ventricle volume.
  • Histological analysis confirmed reduced ventricular wall damage in acetazolamide-treated rats.

Conclusions:

  • Acetazolamide effectively reduced hydrocephalus in a rat model of thrombin-induced intraventricular hemorrhage.
  • The mechanism involves the reduction of cerebrospinal fluid production by acetazolamide.
  • Acetazolamide shows potential as a therapeutic agent for managing hydrocephalus after intraventricular hemorrhage.